Among systemic therapies, several multi-kinase inhibitors that target RAF/MEK/ERK pathway in tumor cells and VEGFR tyrosine kinases in tumor vasculature, have demonstrated promising clinical benefit in patients with ACC [8, 46, 123, 124]. Here, MAP2K7 is linked to neoplasm.